Your Next Investor Should Be More Than an Investor

3 Sep

-An Interview with Onelin Capital

Judy Lee
General Manager, Onelin Capital

Candice He
Global Investment Strategist, LSN

Life Science Nation (LSN) is pleased to announce that Onelin Capital Corporation will be a Title Sponsor of the upcoming Digital RESI Conference, taking place September 14-16. Onelin Capital, a multi-billion-dollar global conglomerate, is actively seeking life science startups interested in investments and business opportunities in the Asia market. In this interview, Judy Lee, the General Manager of Onelin Capital, will share how Onelin helped its portfolio companies to grow, what kinds of companies Onelin is seeking for future collaboration, and how Onelin is participating in the upcoming RESI.

Candice He (CH): Could you briefly introduce Onelin Capital and its mandate for early-stage life science investments?

Judy Lee (JL): Thank you, Candice. A bit about us, we are a family office backed by a 30+ year real estate global conglomerate with offices in Silicon Valley, Seattle, and Asia. We are active tech investors, meaning that our investments need to be tech-enabled, but tend to be more long-term focused. We invest across various asset classes, including direct investments into early-stage companies from Seed to Series A. Currently, we have close to 30 companies within our portfolio that are direct investments. We also participate in funds, secondaries, SPVs, etc.

For early-stage life science investments, generally, we are interested in companies that are in the analytics, diagnostics, and early prevention space as they tend to be more healthtech-related. However, if the company has a strategic value for us (meaning has an interest in going to Asia), we are still interested in the partnership/investment side.

CH: Could you please share an example or two of the life sciences companies that Onelin Capital has invested in so that our readers can know more about what kinds of companies Onelin is looking for?

JL: Of course! Our venture investment arm is Constellar Ventures. Through Constellar Ventures, we have invested in several healthtech/life sciences companies, including BioTrillion and Patchd Medical.

BioTrillion is developing a mobile health technology platform called BioEngine4D™ to digitally detect drugs and diseases by measuring data from life, analyzing it through computational advancements in machine vision and artificial intelligence, and applying it back for life. Its mission is to enable smart device technology to empower ordinary consumers with extraordinary health abilities.

Patchd Medical leverages deep learning and off-the-shelf wearables to predict the onset of sepsis in high-risk patients who have been discharged from the hospital. Its early studies have shown it can predict sepsis 8 hours earlier, and more accurately, than existing standards of care.

Both companies are healthtech-related and are much needed in the future of healthcare, especially during Covid-19. Both seek to focus on early detection, diagnostics, and remote monitoring.

CH: I noticed both companies applied to the RESI Innovation Challenge for the first time. Does Onelin always help portfolio companies to connect with useful resources and platforms like RESI? In addition to the investments, how does Onelin help portfolio companies to grow?

JL: Every single one of our investments is quite important to us. We are a family office, and our investments become part of this family. We are always open to lending a helping hand to our portfolio companies, including but not limited to connecting our portfolio companies to useful resources, introducing them to our later-stage investors, providing insights if we are able, and aligning them with strategic partners from a business expansion and development perspective. After all, we are an investor, and we want to see them succeed.

CH: As the RESI Title Sponsor, Onelin Capital is selecting 20 companies to join Onelin PitchBuzz FREE of charge. For the readers who are interested in applying, could you tell them what you look for in potential portfolio companies?

JL: Onelin Capital is looking for all life sciences-related companies who are seeking partnerships in the Asia market to work with, and tech-enabled startups for investments. If you are not selected for our PitchBuzz this time, don’t worry! We still want to get in touch with you and explore opportunities working together. Please don’t hesitate to reach out to us at onelinsv@onelincapital.com.

CH: Thank you very much for the interview, Judy.

For our readers who want to know more about Onelin Capital, RSVP for the live investor panel discussion that will be moderated by Judy, at 8 PM EST, September 10. The full panel lineup is as below. Please also check out Onelin’s website at https://www.onelincapital.com/

Moderator:

Judy Lee
General Manager
Onelin Capital

Judy is a veteran in the investment world with 15+ years of both public and private equities experience.  Coupled with years of global marketing experience, Judy is energetic and widely regarded as a growth catalyst with contagious passion. Judy currently serves as Onelin Capital Principal & General Manager, overseeing the entire family office’s operation as well as fund investments.

Judy’s LinkedIn: https://www.linkedin.com/in/thejudylee/

Panelists:

Weiyong Sun
Senior Director, Specialty Medicine Search & Evaluation
Daiichi Sankyo

Dr. Weiyong Sun is currently Senior Director, Searching and Evaluation, Global Business Development at Daiichi Sankyo Group. He joined Daiichi Sankyo Japan in April 2002. He was involved in a broad range of R&D activities from target discovery to clinical development of a number of anti-diabetes drugs. In October 2007, Dr. Sun was elected to be assigned to work for Daiichi Sankyo Research Institute in the U.S. He was responsible for identifying and evaluating in-licensing, partnering and research collaboration opportunities. His current focus is in Immunology Cardio-Renal, Ophthalmology and Rare Disease. Dr. Sun received an M.D. from Beijing Medical University (now Peking University Medical School), a Ph.D. in Biochemistry from the University of Tokyo and an MBA from Columbia Business School. He was a postdoctoral fellow in the Blood Research Institute, Medical College of Wisconsin.

Yao Li Ho
Senior Director of Business Development
LYFE Capital

Yao Ho is a Senior Director of Business Development at LYFE Capital. Previously, he was a part of Yangtze River Pharmaceutical Group, where he was a BD Manager. At Yangtze River Pharmaceutical Group, he was part of a team that would help the parent organization source, evaluate, coordinate due diligence and negotiate with potential international partners for pharmaceuticals, biologics and medical devices. Yao has also worked at various diagnostics, nanotechnology and digital health startups where he started as an R&D Engineer and was a member of the founding team at other companies. Yao is an MBA graduate from Tsinghua University in partnership with MIT and Bachelor’s in Biomedical Engineering from UC-Irvine with a specialization in bio-photonics and research in microfluidics.

Haolin Sung
Managing Partner
Chaperone Investment

Haolin Sung is the founder and the managing partner at Chaperone Investment, a Taiwan based VC fund focusing on angel and early stage investment in healthcare and biotech sector. He has 10+ years of experience in this field and serves as a board director for several companies including Panlabs, MountainVet, and was the board director at Pharmigene. Mr. Sung also serves in critical roles at several of the Chaperone portfolio companies including Celtech and Caliway to assist these companies in funding and business development/ licensing activities. Prior to Chaperone Investment, Mr. Sung was the director of the direct investment department for Diamond Biofund, the largest Biotech VC in Taiwan and the deputy director of Microbio Biotech Shanghai. He also worked for First Capital Management as a healthcare/biotech industry analyst. Mr. Sung earned his EMBA at Columbia University and London business school and has a B.S. in Biochemistry from Dong Hwa University.

Haruhiko Sugino
Director, Global Business Development
Otsuka Pharmaceuticals

Currently on an expatriate assignment from Japan, Haru Sugino is leading the global scouting activities for Otsuka Pharmaceutical Co., Ltd working closely with Otsuka’s US and EU BD affiliates. Haru is a part of Otsuka’s evaluation and negotiation team, charged with identifying, evaluating, and negotiating transactions to in-license new innovative compounds that address unmet medical needs in CNS/neuro and renal diseases for both global development or for regional development in Japan and Asia. Haru has been with Otsuka for 22 years in various roles, including sales, pre-clinical drug discovery, clinical R&D, commercial, and business development. Haru has a PhD for neuropharmacology, and moved to business development in 2016 after successfully launching a drug in US on which he worked for 10 years from pre-clinical discovery through to commercialization.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: